SCHEDULE 13G/A: T. Rowe Price Investment Management Discloses 11.6% Stake in Immatics NV

T. Rowe Price Investment Management, Inc. has reported a beneficial ownership of 11.6% of Immatics NV's common stock as of February 28, 2025.

Summary

• T. Rowe Price Investment Management, Inc. filed an Amendment No. 2 to Schedule 13G regarding its beneficial ownership in Immatics NV.
• As of February 28, 2025, T. Rowe Price Investment Management, Inc. beneficially owns 14,152,558 shares of Immatics NV's common stock.
• This ownership represents 11.6% of the total class of securities.
• The firm holds sole voting power over 14,119,764 shares and sole dispositive power over 14,152,558 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant stake by a reputable institutional investor like T. Rowe Price is generally a positive signal for the company, indicating investor confidence and potentially long-term interest. It doesn't contain negative news about the company itself.

Positives

• A significant institutional investor, T. Rowe Price Investment Management, Inc., holds a substantial 11.6% stake in Immatics NV, indicating confidence in the company.
• The filing explicitly states that the shares were acquired and are held in the ordinary course of business, not for control purposes, suggesting a long-term investment perspective.

Future Outlook

This document does not provide future outlook or guidance from the issuer, Immatics NV. It is a disclosure of beneficial ownership by an institutional investor.

Industry Context

The filing of a Schedule 13G by a major institutional investor like T. Rowe Price indicates significant interest and a substantial position in Immatics NV, a common occurrence for companies that attract institutional capital in their respective sectors, often biotechnology or pharmaceuticals given Immatics NV's name.

Comparison to Industry Standards

• While a 13G filing itself doesn't offer direct performance comparisons, the acquisition of an 11.6% stake by a prominent asset manager like T. Rowe Price is a strong signal of institutional confidence.
• Such a significant stake is comparable to other large institutional holdings seen in emerging biotech or specialized pharmaceutical companies, where major funds often take substantial positions to influence or benefit from long-term growth.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially attract further investment, positively impacting share price perception.

Key Dates

Keywords

Immatics NV, T. Rowe Price Investment Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, N44445109